|
Name |
Elsinochrome B
|
| Molecular Formula | C30H26O10 | |
| IUPAC Name* |
12-acetyl-9,16-dihydroxy-13-(1-hydroxyethyl)-5,10,15,20-tetramethoxyhexacyclo[12.8.0.02,11.03,8.04,21.017,22]docosa-1(14),2(11),3(8),4(21),5,9,15,17(22),19-nonaene-7,18-dione
|
|
| SMILES |
CC(C1C(C2=C3C4=C1C(=C(C5=C4C(=C6C3=C(C(=O)C=C6OC)C(=C2OC)O)C(=CC5=O)OC)O)OC)C(=O)C)O
|
|
| InChI |
InChI=1S/C30H26O10/c1-9(31)15-16(10(2)32)26-24-22-18(28(36)30(26)40-6)12(34)8-14(38-4)20(22)19-13(37-3)7-11(33)17-21(19)23(24)25(15)29(39-5)27(17)35/h7-9,15-16,31,35-36H,1-6H3
|
|
| InChIKey |
XOLHPTZQLUNXFP-UHFFFAOYSA-N
|
|
| Synonyms |
Elsinochrome B; NSC671196; 24512-58-1; 12-acetyl-9,16-dihydroxy-13-(1-hydroxyethyl)-5,10,15,20-tetramethoxyhexacyclo[12.8.0.02,11.03,8.04,21.017,22]docosa-1(14),2(11),3(8),4(21),5,9,15,17(22),19-nonaene-7,18-dione; acetyl-dihydroxy-(1-hydroxyethyl)-tetramethoxy-[?]dione; CHEMBL1975230; NSC-671196; NCI60_025145; 1-Acetyl-1,2-dihydro-5,10-dihydroxy-2-(1-hydroxyethyl)-3,7,8,12-tetramethoxybenzo[ghi]perylene-4,11-dione; 1-Acetyl-5,10-dihydroxy-2-(1-hydroxyethyl)-3,7,8,12-tetramethoxy-1,2-dihydrobenzo[ghi]perylene-4,11-dione
|
|
| CAS | NA | |
| PubChem CID | 495865 | |
| ChEMBL ID | CHEMBL1975230 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 546.5 | ALogp: | 3.4 |
| HBD: | 3 | HBA: | 10 |
| Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 149.0 | Aromatic Rings: | 6 |
| Heavy Atoms: | 40 | QED Weighted: | 0.209 |
| Caco-2 Permeability: | -5.15 | MDCK Permeability: | 0.00000954 |
| Pgp-inhibitor: | 0.162 | Pgp-substrate: | 0.946 |
| Human Intestinal Absorption (HIA): | 0.94 | 20% Bioavailability (F20%): | 0 |
| 30% Bioavailability (F30%): | 0.031 |
| Blood-Brain-Barrier Penetration (BBB): | 0.011 | Plasma Protein Binding (PPB): | 72.78% |
| Volume Distribution (VD): | 1.076 | Fu: | 37.72% |
| CYP1A2-inhibitor: | 0.182 | CYP1A2-substrate: | 0.977 |
| CYP2C19-inhibitor: | 0.024 | CYP2C19-substrate: | 0.415 |
| CYP2C9-inhibitor: | 0.338 | CYP2C9-substrate: | 0.87 |
| CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.196 |
| CYP3A4-inhibitor: | 0.027 | CYP3A4-substrate: | 0.059 |
| Clearance (CL): | 1.944 | Half-life (T1/2): | 0.194 |
| hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.024 |
| Drug-inuced Liver Injury (DILI): | 0.844 | AMES Toxicity: | 0.164 |
| Rat Oral Acute Toxicity: | 0.035 | Maximum Recommended Daily Dose: | 0.138 |
| Skin Sensitization: | 0.066 | Carcinogencity: | 0.005 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.617 |
| Respiratory Toxicity: | 0.067 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003190 | ![]() |
0.831 | D09DHY | ![]() |
0.324 | ||
| ENC001118 | ![]() |
0.831 | D06GCK | ![]() |
0.321 | ||
| ENC004029 | ![]() |
0.742 | D02LZB | ![]() |
0.298 | ||
| ENC001454 | ![]() |
0.672 | D03RTK | ![]() |
0.263 | ||
| ENC001491 | ![]() |
0.521 | D01FFA | ![]() |
0.238 | ||
| ENC003042 | ![]() |
0.463 | D0V6OA | ![]() |
0.237 | ||
| ENC001501 | ![]() |
0.409 | D04TDQ | ![]() |
0.237 | ||
| ENC002093 | ![]() |
0.409 | D0C1SF | ![]() |
0.236 | ||
| ENC002002 | ![]() |
0.400 | D01XWG | ![]() |
0.234 | ||
| ENC003154 | ![]() |
0.391 | D0WY9N | ![]() |
0.233 | ||